Enzolytics Inc (OTCMKTS:ENZC) Stock Sees High Volatility: What To Do Now?
One of the stocks to have gained considerable traction among investors over the course of the year so far is that of Enzolytics Inc (OTCMKTS:ENZC). Yesterday, the stock was in focus among investors once again and ended up clocking gains of as much as 19%.
There was no fresh news about the company yesterday but in case of such a rally, it might be a good move on the part of investors to perhaps consider taking a closer look at the latest developments at Enzolytics. The last time any news emerged about the company was last week when it announced Stave Sharabura was appointed as the President of RobustoMed Inc, a fully owned subsidiary of Enzolytics.
It is a major appointment for RobustoMed considering the fact that the company is currently working on the implementation of a new business model. In this new model, the company is going to work on creating global partnerships centered on medicines that are at a development stage. Sharabura is expected to help the company considerably in this regard.
He is not only going to be involved in boosting revenues at RobustoMed but also work on creating important partnerships all over the world. Some of the markets in which he is going to focus include Costa Rica and Brazil among other emerging markets. Sharabura is an experienced executive and has extensive experience in the world of international affairs. Hence, this appointment seems to have come as a source of excitement for many market participants.
Enzolytics Inc (ENZC) Stock Gains Further Momentum: What’s Ahead?
If you are into micro-cap stocks then you might have noticed that Enzolytics Inc (OTCMKTS:ENZC) has emerged as one of the major movers this year so far and the rally in the stock continued over the course of the past week. During that period, the stock attracted plenty of investors and ended up clocking gains of as much as 22%.
Considering the magnitude of the gains made by the stock it might be a good idea for investors to take a look at a development earlier this week that might have brought about the latest rally. The company announced that it inked a letter of intent with Creative Biolabs which stipulates that the two companies are going to work on the commercialization and development of HTLV-1 monoclonal antibodies.
The two companies are going to accomplish that by combining their technologies. It was a significant development for Enzolytics considering the fact that at this point in time there are no antiviral medicines or vaccines that can tackle HTLV-1. As a result, the fact that the company has now decided to collaborate on a project on the same thing has come as a source of considerable excitement for investors.
In this project, the Artificial Intelligence method that belongs to Enzolytics is going to be deployed for the purpose of identifying the conserving immutable target sites that can be found on the HTLV-1 virus. Creative will be responsible for testing the efficacy and neutralising capabilities of the monoclonal antibodies, among other duties.
Enzolytics Inc (ENZC) Stock Continues to See Selling Pressure: Where is The Bottom?
There have been many small cap stocks which have made considerable gains this year and one of the more notable ones in that regards is the Enzolytics Inc (OTCMKTS:ENZC) stock.
The Enzolytics stock was on the move yesterday and jumped by 13% to takes its gains over the course of the past week to as much as 25%. Although the gains made by the stock are certainly eye-catching, it is also necessary for investors to remember that the rally in the stock might be related to an announcement made by Enzolytics back on June 14. The company announced at the time that it has created definite plans by way of which it wants to take its ITV-1 anti-HIV therapy to clinical trials.
In addition to that, plans have also been made with regards to the distribution of the product in Europe. More importantly, the company also expects to generate considerable revenue from this product and hence, the excitement around the Enzolytics stock is perhaps understandable. In this regard, it should be pointed out that the product had been progressing towards a certification under the control of the Bulgarian Drug Agency.
Although that process was discontinued, it is necessary to note that there was considerable progress made and in addition to that, positive results had also emerged from clinical trials of patients. The positive results from the discontinued trial have given Enzolytics the confidence that the clinical trials it has planned under the control of the European Medicines Agency are going to be successful.
Enzolytics (ENZC) Stock Attempts To Recovery: Will The Rally Continue?
In the past two weeks, the Enzolytics Inc (OTCMKTS:ENZC) stock has been on the radars of many investors and that becomes far more apparent from the price action in the stock. The stock has recorded gains of 35% during that period and the rally continued on Tuesday.
Yesterday, it jumped by as much as 15.5% and in this sort of situation; it might be a good idea for investors to take a closer look at the company. One of the more important positive triggers for the stock came about on May 26 when the company announced that it had managed to identify immutable sites on the HTLV-1 virus.
It is a major development since it is going to help Enzolytics in its work to product monoclonal antibodies that are supposed to work against the HTLV-1 virus. In this regard, investors need to keep in mind that at this point there are no effective vaccines in the market that can actually tackle the HTVL-1 virus.
While this discovery was an important factor behind the rally in the Enzolytics stock, it is important to mention that there were some other important developments as well. In the middle of May, it was announced that Enzolytics collaborated with Intel Corporation to publish a white paper.
The white paper, titled “Optimizing Empathetic A.I. to Cure Deadly Diseases”, pointed out that the innovative approach of Enzolytics and the artificial intelligence analytics tools of Intel could be combined to produce effective treatments meant for all types of virus infections. This white argues that in the future the aim of healthcare is going to be more anticipatory than reactionary.
Back in April the company had also made an announcement with regards to the sort of progress it has made on a range of initiatives including the one related to its multiple therapeutics platform. It is now going to be interesting to see if the Enzolytics stock can maintain its momentum in the coming days.